EXECUTION VERSION


 




SECURITIES
PURCHASE AGREEMENT


 


Dated as of April 14, 2106


Xtant Medical Holdings, Inc.

600 Cruiser Lane

Belgrade, Montana 59714


Ladies and Gentlemen:


 


Each of the undersigned (each, an “Investor”)
hereby confirms its agreement with you as follows:


		1.	This Securities Purchase Agreement (the “Agreement”) is made as of
the date hereof between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and the Investors
listed on the signature pages hereto (the “Investors”).



		2.	The Company is proposing to issue and sell to the Investors $2,238,166.45 aggregate
principal amount of convertible senior notes due 2021 (the “Securities”), which are convertible into
shares of the Company’s common stock, par value $0.000001 per share (the “Common Stock”). The Securities
will be entitled to the benefits of a Registration Rights Agreement (the “Registration Rights Agreement”), to be entered
into among the Company and the Investors, pursuant to which the Company will agree, among other thing, to file and cause to become
effective under the Securities Act of 1933, as amended (the “Securities Act”), a registration statement covering the
resale of the Securities and the Common Stock issuable upon conversion of the Securities.



		3.	The Securities shall have the terms set forth in each of the convertible promissory notes (the
“Notes”) in the form attached hereto as Exhibit A, to be issued on the date hereof to each of the Investors.




		4.	The Company and each Investor agrees that, upon the terms and subject to the conditions set
forth herein, each Investor will purchase from the Company and the Company will issue and sell to each Investor the aggregate principal
amount of Securities set forth below on such Investor’s signature page for the aggregate purchase price set forth below on such
Investor’s signature page. The Securities shall be purchased pursuant to the Terms and Conditions for Purchase of Securities attached
hereto as Annex A and incorporated herein by reference as if fully set forth herein.



 






    	 



     

    
EXECUTION VERSION


 



Aggregate Principal Amount of Securities the Investor
Agrees to Purchase:


 


$1,428,552.78


 


Aggregate Purchase Price of such Securities:
$1,428,552.78


 


Please confirm that the foregoing correctly
sets forth the agreement between us by signing in the space provided below for that purpose.


 


	AGREED AND ACCEPTED BY:	
	 	 
	 	 
	
        


 





         

         

	 	 
	
        Xtant Medical Holdings, Inc.

        a Delaware corporation

         

         
	
        Name of Investor: ROS Acquisition Offshore LP

         

	By: /s/ Daniel Goldberger	By: /s/ Samuel D. Isaly
	Name: Daniel Goldberger	Print Name: Samuel D. Isaly
	Title: Chief Executive Officer	Title: Managing Member
	 	Address: 601 Lexington Avenue, 5th Floor
	 	New York, NY 10022
	 	Tax ID No.: 98-1023042
	 	Settlement Contact Name: J. Christopher LiPuma
	 	Telephone: 212-739-6415
	 	Email Address: Lipumac@orbimed.com


 






    	 



     

    

Aggregate Principal Amount of Securities
the Investor Agrees to Purchase:


$809,613.67


Aggregate Purchase Price of such Securities:
$809,613.67


Please confirm that the foregoing correctly
sets forth the agreement between us by signing in the space provided below for that purpose.


	AGREED AND ACCEPTED BY:	
         

         

         

         

	
         


 



         

         

	 	 
	
        Xtant Medical Holdings, Inc.

        a Delaware corporation

         

         
	
        Name of Investor: OrbiMed Royalty Opportunities II,
        LP

         

	By:  /s/ Daniel Goldberger	By: /s/ Samuel D. Isaly
	Name: Daniel Goldberger	Print Name: Samuel D. Isaly
	Title: Chief Executive Officer	Title: Managing Member
	 	Address: 601 Lexington Avenue, 5th Floor
	 	New York, NY 10022                              
	 	Tax ID No.: 32-0457118


 






    	 	2	 



     

    

ANNEX
A TO THE SECURITIES PURCHASE AGREEMENT

TERMS AND CONDITIONS FOR PURCHASE OF SECURITIES





		1.	Authorization and Sale of Securities. The Company is proposing to sell $2,238,166.45
aggregate principal amount of the Securities to the Investors.




		2.	Agreement to Sell and Purchase the Securities.



		2.1	Upon the terms and subject to the conditions hereinafter set forth, at the Closing (as defined in Section 3), the Company will
sell to each Investor, and each Investor will purchase from the Company, the aggregate principal amount of Securities set forth
on such Investor’s signature page hereto at the purchase price set forth on such signature page.



		3.	Closings and Delivery of Securities and Funds.



		3.1	The completion of the purchase and sale of the Securities (the
                                         “Closing”) shall occur on April 14, 2016 (the “Closing Date”).






		3.2	The Company’s obligation to issue and sell the Securities to the Investors shall be subject to the following conditions, any
one or more of which may be waived by the Company: (a) the accuracy of the representations and warranties made by the Investors
and (b) the fulfillment of those undertakings of the Investors to be fulfilled prior to the Closing.



		3.3	Each Investor’s obligation to accept delivery of the Securities and to pay for the Securities shall be subject to the
following conditions: (a) each of the representations and warranties of the Company made in Section 4 hereof shall be accurate
in all material respects as of the Closing Date; (b) delivery of an officer’s certificate dated as of the Closing Date regarding
the accuracy in material respects of the Company’s representations and warranties and addressing such other matters as are
customarily addressed in closing certificates; (c) delivery to the Investors of a customary secretary’s certificate in form
reasonably acceptable to the Investors; (d) the Company and the Investors shall have executed the Registration Rights Agreement;
(e) the Company shall have issued a Note, in form and substance satisfactory to the Investors, to each of the Investors and (f)
the Company shall have furnished to the Investors such further certificates and documents as the Investors may reasonably request.



		3.4	At the Closing, each Investor shall remit by wire transfer the amount of funds equal to the aggregate purchase price for the
Securities being purchased by such Investor to the following account designated by the Company:




	 	Bank Name:	SIL VLY BK SJ
	 	Bank Address:	3003 Tasman Drive, Santa Clara, CA 95054
	 	Beneficiary Name:  	Bacterin International Inc.
	 	Account Number:  	3301057621
	 	Routing Number:  	121140399




 






    	 	A-1	 



     

    

 



		4.	Representations, Warranties and Covenants of the Company.




 


The Company hereby represents and warrants to, and covenants with, each Investor that:


 

		4.1	When the Notes are issued and delivered pursuant to this Agreement, such Notes will not be of the same class
(within the meaning of Rule 144A under the Securities Act) as securities of the Company that are listed on a national securities
exchange registered under Section 6 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or that are quoted in a U.S. automated inter-dealer quotation system.



		4.2	Assuming the accuracy of each Investor’s representations and warranties in Section 5, the purchase and
resale of the Notes pursuant hereto are exempt from the registration requirements of the Securities Act.



		4.3	No form of general solicitation or general advertising within the meaning of Regulation D under the Securities
Act (including, but not limited to, advertisements, articles, notices or other communications published in any newspaper, magazine
or similar medium or broadcast over television or radio, or any seminar or meeting whose attendees have been invited by any general
solicitation or general advertising) (each, a “General Solicitation”) was used by the Company, any of
its affiliates or any of its representatives (other than you, as to whom the Company makes no representation) in connection with
offer and sale of the Notes.



		4.4	None of the Company or any other person acting on its behalf has sold or issued any securities that would
be integrated with the offering of the Notes contemplated by this Agreement pursuant to the Securities Act, the rules and regulations
thereunder or the interpretations thereof by the Securities
and Exchange Commission (the “Commission”) in a manner that would require the registration, under the Securities
Act, of the sale of the Notes contemplated by this Agreement.






		4.5	Each of the Company and its subsidiaries has been duly organized, is validly existing and in good standing as a corporation,
partnership or limited liability company, as applicable, under the laws of its jurisdiction of organization and is duly qualified
to do business and in good standing as a foreign corporation or other business entity in each jurisdiction in which its ownership
or lease of property or the conduct of its businesses requires such qualification, except where the failure to be so qualified
or in good standing could not, individually or in the aggregate, reasonably be expected to (i) have a material adverse effect on
the condition (financial or otherwise), results of operations, stockholders’ equity, properties, business or prospects of
the Company and its subsidiaries taken as a whole or (ii) materially interfere with the consummation of the transactions contemplated
hereby (collectively, a “Material Adverse Effect”). Each of the Company and its subsidiaries has all
power and authority necessary to own or hold its properties and to conduct the businesses in which it is engaged. As of the date
of this Agreement, the Company has no subsidiaries other than Bacterin International, Inc., X-spine Systems Inc., X-spine Sales
Corporation and Xtant Medical, Inc. and no “significant subsidiaries” (as defined in Rule 405 under the Securities
Act) other than Bacterin International, Inc. and X-spine Systems Inc.







    	 	A-2	 



     

    

 


		4.6	The Company has an authorized capitalization as set forth in the publicly available Annual Report on Form 10-K filed with the
Commission for the fiscal year ended December 31, 2015 (the “2015 Annual Report”), and all of the issued
shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and non-assessable. All
of the issued shares of capital stock or other ownership interest of each subsidiary of the Company have been duly authorized and
validly issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of all liens,
encumbrances, equities or claims, except for such liens, encumbrances, equities or claims as could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.



		4.7	The Company has all requisite corporate power and authority to execute, issue, sell and perform its obligations under the Notes.
The Notes have been duly authorized by the Company and, when duly executed by the Company, will be validly issued and delivered
and will constitute valid and binding obligations of the Company entitled to the benefits of the Registration Rights Agreement,
enforceable against the Company in accordance with their terms, except as such enforceability may be limited by bankruptcy, fraudulent
conveyance, insolvency, reorganization, moratorium, and other laws relating to or affecting creditors’ rights generally and
by general equitable principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).



		4.8	The Company has all requisite corporate power and authority to execute, deliver and perform its obligations under the Registration
Rights Agreement. The Registration Rights Agreement has been duly and validly authorized by the Company, and upon its execution
and delivery and, assuming due authorization, execution and delivery by the other parties thereto, will constitute the valid and
binding agreement of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may
be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium, and other laws relating to or affecting
creditors’ rights generally and by general equitable principles (regardless of whether such enforceability is considered
in a proceeding in equity or at law).



		4.9	The Company has all the requisite corporate power and authority to issue the Common Stock issuable upon conversion of the Notes
(the “Underlying Common Stock”). The Underlying Common Stock has been duly and validly authorized by
the Company and, and when issued upon conversion of the Notes, in accordance with the terms of the Notes, will be validly issued,
fully paid and non-assessable, and the issuance of the Underlying Common Stock will not be subject to any preemptive or similar
rights.







    	 	A-3	 



     

    

 


		4.10	The Company has all requisite corporate power to execute, deliver and perform its obligations under this Agreement. This Agreement
has been duly and validly authorized, executed and delivered by the Company



		4.11	The issue and sale of the Notes, the issuance of the Underlying Common Stock upon conversion of the Notes, the execution, delivery
and performance by the Company of the Notes, the Registration Rights Agreement and this Agreement and the consummation of the transactions
contemplated hereby and thereby, will not (i) conflict with or result in a breach or violation of any of the terms or provisions
of, impose any lien, charge or encumbrance upon any property or assets of the Company or its subsidiaries, or constitute a default
under, any indenture, mortgage, deed of trust, loan agreement, license, lease or other agreement or instrument to which the Company
or any of its subsidiaries is a party or by which any of them is bound or to which any of their respective properties or assets
is subject, (ii) result in any violation of the provisions of the charter or by-laws (or similar organizational documents) of the
Company or any of its subsidiaries, or (iii) result in any violation of any statute or any judgment, order, decree, rule or regulation
of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their respective
properties or assets, except, with respect to clauses (i) and (iii), conflicts or violations that could not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect.



		4.12	No consent, approval, authorization or order of, or filing, registration or qualification with any court or governmental agency
or body having jurisdiction over the Company or any of its subsidiaries or any of their respective properties or assets is required
for the issue and sale of the Notes, the issuance of the Underlying Common Stock upon conversion of the Notes, the execution, delivery
and performance by the Company of the Notes, the Registration Rights Agreement and this Agreement, and the consummation of the
transactions contemplated hereby, except for such consents, approvals, authorizations, orders, filings, registrations or qualifications
as may be required under state securities or Blue Sky laws in connection with the purchase of the Notes.



		4.13	The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) of the
Exchange Act) that complies with the requirements of the Exchange Act and that has been designed by, or under the supervision of,
the Company’s principal executive and principal financial officers, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles in the United States. The Company maintains internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorization, (ii) transactions
are recorded as necessary to permit preparation of the Company’s financial statements in conformity with accounting principles
generally accepted in the United States and to maintain accountability for its assets, (iii) access to the Company’s assets
is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability
for the Company’s assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. As of the date of the most recent balance sheet of the Company and its consolidated subsidiaries reviewed or
audited by EKS&H LLP and the audit committee of the board of directors of the Company, there were no material weaknesses in
the Company’s internal controls.






    	 	A-4	 



     

    

 


		4.14	The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act),
(ii) such disclosure controls and procedures are designed to ensure that the information required to be disclosed by the Company
and its subsidiaries in the reports they file or submit under the Exchange Act is accumulated and communicated to management of
the Company and its subsidiaries, including their respective principal executive officers and principal financial officers, as
appropriate, to allow timely decisions regarding required disclosure to be made; and (iii) such disclosure controls and procedures
are effective in all material respects to perform the functions for which they were established.



		4.15	Since the date of the most recent balance sheet of the Company and its consolidated subsidiaries reviewed or audited by EKS&H
LLP and the audit committee of the board of directors of the Company, (i) the Company has not been advised of or become aware of
(A) any significant deficiencies in the design or operation of internal controls, that could adversely affect the ability of the
Company or any of its subsidiaries to record, process, summarize and report financial data, or any material weaknesses in internal
controls, and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in
the internal controls of the Company and each of its subsidiaries; and (ii) there have been no significant changes in internal
controls or in other factors that could significantly affect internal controls, including any corrective actions with regard to
significant deficiencies and material weaknesses.



		4.16	There is and has been no failure on the part of the Company and any of its directors or officers, in their capacities as such,
to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith.



		4.17	Since the date of the latest audited financial statements included in the Public Disclosure Documents (as defined below) and
except as disclosed therein, neither the Company nor any of its subsidiaries has (i) sustained any loss or interference with its
business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute
or court or governmental action, order or decree, (ii) issued or granted any securities (other than pursuant to (x) employee benefit
plans, qualified stock option plans, other employee compensation plans or non-employee director compensation programs (collectively,
“Compensation Plans”) in existence on the date hereof and described in the Public Disclosure Documents
or (y) options, warrants or rights outstanding on the date hereof, (iii) incurred any liability or obligation, direct or contingent,
other than liabilities and obligations that were incurred in the ordinary course of business, (iv) entered into any transaction
not in the ordinary course of business (other than as described in the Public Disclosure Documents (without giving effect to any
supplements or amendments thereto after the execution and delivery of this Agreement), or (v) declared or paid any dividend on
its capital stock, and, since such date, there has not been any change in the capital stock, partnership or limited liability company
interests, as applicable, or long-term debt of the Company or any of its subsidiaries (other than as described in the Public Disclosure
Documents (without giving effect to any supplements or amendments thereto after the execution and delivery of this Agreement))
or any adverse change, or any development involving a prospective adverse change, in or affecting the condition (financial or otherwise),
results of operations, stockholders’ equity, properties, management, business or prospects of the Company and its subsidiaries,
taken as a whole, in each case except as could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. The reports required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, together with any materials filed or furnished by the Company under the Exchange Act, whether or not any such reports
were required, are referred to herein, collectively, as the “Public Disclosure Documents”.







    	 	A-5	 



     

    

 


		4.18	The Company and each of its subsidiaries has good and marketable title in fee simple to all real property and good and marketable
title to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects, except to the
extent such liens, encumbrances and defects do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company or any of its subsidiaries. All assets held under lease
by the Company or any of its subsidiaries are held by them under valid, subsisting and enforceable leases, with such exceptions
as do not materially interfere with the use made and proposed to be made of such assets by the Company or any of its subsidiaries.



		4.19	The Company and each of its subsidiaries have, and have operated in compliance with, such permits, licenses, patents, franchises,
certificates of need, exemptions, clearances and other approvals or authorizations of governmental or regulatory authorities (“Permits”)
as are necessary under applicable law to own their properties and conduct their businesses in the manner described in the Public
Disclosure Documents, except for any of the foregoing that could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. The Company and each of its subsidiaries have fulfilled and performed all of its obligations
with respect to the Permits, and no event has occurred that allows, or after notice or lapse of time would allow, revocation or
termination thereof or results in any other impairment of the rights of the holder or any such Permits, except for any of the foregoing
that could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the Company,
nor any of its subsidiaries has received written notice of any revocation, termination or modification of any such Permits or otherwise
has any reason to believe that any such Permits will be revoked, terminated or modified or not be renewed in the ordinary course.







    	 	A-6	 



     

    

 


		4.20	The Company and its subsidiaries own, or have obtained valid and enforceable licenses for, or other rights to use, the inventions,
patent applications, patents, trademarks (both registered and unregistered), tradenames, service names, copyrights, trade secrets
and other proprietary information described in Public Disclosure Documents as being owned or licensed by them or which are necessary
for the conduct of their respective businesses as currently conducted or as proposed to be conducted (including the commercialization
of products or services described in the Public Disclosure Documents as under development), except where the failure to own, license
or have such rights could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect (collectively,
“Intellectual Property”); except as disclosed in Public Disclosure Documents, and except as could not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) there are no third parties who
have or, to the Company’s knowledge, will be able to establish rights to any Intellectual Property, except for, and to the
extent of, the ownership rights of the owners of the Intellectual Property which the Public Disclosure Documents disclose is licensed
to the Company or any of its subsidiaries; (ii) to the Company’s knowledge, there is no infringement by third parties of
any Intellectual Property; (iii) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others challenging the Company’s or its subsidiaries’ rights in or to any Intellectual Property, and the
Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (iv) there
is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity,
enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which could form a reasonable basis
for any such action, suit, proceeding or claim; (v) there is no pending or, to the Company’s knowledge, threatened action,
suit, proceeding or claim by others that the Company or any of its subsidiaries infringes or otherwise violates (or would, upon
the commercialization of any product or service described in the Public Disclosure Documents as under development, infringe or
violate) any patent, trademark, tradename, service name, copyright, trade secret or other proprietary rights of others, and the
Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (vi) the Company
and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to
the Company or any of its subsidiaries, and all such agreements are in full force and effect; (vii) to the Company’s knowledge,
there is no patent or patent application that contains claims that interfere with the issued or pending claims of any of the Intellectual
Property or that challenges the validity, enforceability or scope of any of the Intellectual Property; and (viii) to the Company’s
knowledge, there is no prior art that may render any patent application within the Intellectual Property unpatentable that has
not been disclosed to the U.S. Patent and Trademark Office.







    	 	A-7	 



     

    

 


		4.21	There are no legal or governmental proceedings pending to which the Company or any of its subsidiaries is a party or of which
any property or assets of the Company or any of its subsidiaries is the subject that could, individually or in the aggregate, reasonably
be expected to (i) have a Material Adverse Effect, except as described in the Public Disclosure Documents, or (ii) have a material
adverse effect on the performance by the Company of this Agreement, the Notes or the Registration Rights Agreement or on the consummation
of any of the transactions contemplated hereby or thereby. To the Company’s knowledge, no such proceedings are threatened
or contemplated by governmental authorities or others.



		4.22	Neither the Company nor any of its subsidiaries (i) is in violation of its charter or by-laws (or similar organizational documents),
(ii) is in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the
due performance or observance of any term, covenant, condition or other obligation contained in any indenture, mortgage, deed of
trust, loan agreement, license or other agreement or instrument to which it is a party or by which it is bound or to which any
of its properties or assets is subject, or (iii) is in violation of any statute or any order, rule or regulation of any court or
governmental agency or body having jurisdiction over it or its property or assets or has failed to obtain any license, permit,
certificate, franchise or other governmental authorization or permit necessary to the ownership of its property or to the conduct
of its business, except in the case of clauses (ii) and (iii), to the extent any such default, violation or failure could not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.



		4.23	The Company and its subsidiaries and their respective properties, assets and operations are in compliance with, and the Company
and each of its subsidiaries hold all permits, authorizations and approvals required under, Environmental Laws (as defined below),
except to the extent that failure to so comply or to hold such permits, authorizations or approvals could not, individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Company’ knowledge, there are no past,
present or reasonably anticipated future events, conditions, circumstances, activities, practices, actions, omissions or plans
that, individually or in the aggregate, could reasonably be expected to give rise to any material costs or liabilities to the Company
or any of its subsidiaries under, or to interfere with or prevent compliance by the Company or any of its subsidiaries with, Environmental
Laws; except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, neither
the Company nor any of its subsidiaries (i) is the subject of any investigation, (ii) has received any notice or claim, (iii) is
a party to or affected by any pending or, to the Company’s knowledge, threatened action, suit or proceeding, (iv) is bound
by any judgment, decree or order or (v) has entered into any agreement, in each case relating to any alleged violation of any Environmental
Law or any actual or alleged release or threatened release or cleanup at any location of any Hazardous Materials (as defined below)
(as used herein, “Environmental Law” means any federal, state, local or foreign law, statute, ordinance,
rule, regulation, order, decree, judgment, injunction, permit, license, authorization or other binding requirement, or common law,
relating to health, safety or the protection, cleanup or restoration of the environment or natural resources, including those relating
to the distribution, processing, generation, treatment, storage, disposal, transportation, other handling or release or threatened
release of Hazardous Materials, and “Hazardous Materials” means any material (including, without limitation,
pollutants, contaminants, hazardous or toxic substances or wastes) that is regulated by or may give rise to liability under any
Environmental Law).







    	 	A-8	 



     

    

 


		4.24	The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed
through the date hereof, subject to permitted extensions, and have paid all taxes due, and no tax deficiency has been determined
adversely to the Company or any of its subsidiaries, nor does the Company have any knowledge of any tax deficiencies that have
been, or could reasonably be expected to be asserted against the Company and each of its subsidiaries, that could, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.



		4.25	Neither the Company nor any of its subsidiaries is, and, after giving effect to the offer and sale of the Notes and the application
of the proceeds therefrom, none of them will be, an “investment company” within the meaning of the Investment Company
Act of 1940, as amended, and the rules and regulations of the Commission thereunder.



		4.26	The Company and its affiliates have not taken, directly or indirectly, any action designed to or that has constituted or that
could reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company
in connection with the offering of the Notes.



		4.27	Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, after due inquiry, any director, officer,
agent, employee or other person associated with or acting on behalf of the Company or any of its subsidiaries, has in the course
of its actions for, or on behalf of, the Company or any of its subsidiaries: (i) used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment
to any foreign or domestic government official, “foreign office” (as defined in the Foreign Corrupt Practices Act of
1977, as amended, and the rules and regulations thereunder (collectively, the “FCPA”)) or employee from
corporate funds; (iii) violated or is in violation of any provision of the FCPA, the Bribery Act 2010 of the United Kingdom, as
amended, or any other applicable anti-corruption or anti-bribery laws or statutes; or (iv) made any bribe, rebate, payoff, influence
payment, kickback or other unlawful payment to any domestic government official, foreign official or employee; and the Company
and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have conducted their respective businesses
in compliance with the FCPA, the Bribery Act 2010 of the United Kingdom, as amended, and any other applicable anti-corruption or
anti-bribery laws or statutes, and have instituted and maintain policies and procedures designed to ensure, and which are reasonably
expected to continue to ensure, continued compliance therewith.







    	 	A-9	 



     

    

 


		4.28	The operations of the Company and its subsidiaries are and have been conducted at all times in compliance in all material respects
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money
Laundering Laws”); and no action, suit or proceeding by or before any court or governmental agency, authority or
body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or,
to the knowledge of the Company, threatened.



		4.29	Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, after due inquiry, any director, officer,
agent, employee or affiliate of the Company or any of its subsidiaries (i) is currently subject to or the target of any sanctions
administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department, the U.S. Department of State,
the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively,
“Sanctions”); or (ii) located, organized or resident in a country that is the subject of Sanctions (including,
without limitation, Cuba, Iran, North Korea, Sudan, and Syria); and the Company will not directly or indirectly use the proceeds
of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity, for the purpose of financing the activities of any person, or in any country or territory, that currently is
the subject or target of Sanctions or in any other manner that will result in a violation by any person (including any person participating
in the transaction whether as an underwriter, advisor, investor or otherwise) of Sanctions. The Company and its subsidiaries have
not knowingly engaged in for the past five years, are not now knowingly engaged in, and will not engage in, any dealings or transactions
with any individual or entity, or in any country or territory, that at the time of the dealing or transaction is or was the subject
or target of Sanctions.



		4.30	There are no contracts or other documents that would be required to be described in a registration statement filed under the
Securities Act or filed as exhibits to a registration statement of the Company pursuant to Item 601(b)(10) of Regulation S-K that
have not been described in the Public Disclosure Documents.



		4.31	No relationship, direct or indirect, that would be required to be described in a registration statement of the Company pursuant
to Item 404 of Regulation S-K, exists between or among the Company and its subsidiaries, on the one hand, and the directors, officers,
stockholders, customers or suppliers of the Company and its subsidiaries, on the other hand, that has not been described in the
Public Disclosure Documents.







    	 	A-10	 



     

    

 


		4.32	No labor disturbance by or dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge
of the Company, is imminent that could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.



		4.33	None of the transactions contemplated by this Agreement (including, without limitation, the use of the proceeds from the sale
of the Notes), will violate or result in a violation of Section 7 of the Exchange Act, or any regulation promulgated thereunder,
including, without limitation, Regulations T, U and X of the Board of Governors of the Federal Reserve System.



		4.34	The Company and each of its subsidiaries carry, or are covered by, insurance from insurers of recognized financial responsibility
in such amounts and covering such risks as is adequate for the conduct of their respective businesses and the value of their respective
properties and as is customary for companies engaged in similar businesses in similar industries. All policies of insurance of
the Company and its subsidiaries are in full force and effect; the Company and each of its subsidiaries are in compliance with
the terms of such policies in all material respects; and neither the Company nor any of its subsidiaries has received notice from
any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order
to continue such insurance. Except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect, there are no claims by the Company or any of its subsidiaries under any such policy or instrument as to which any insurance
company is denying liability or defending under a reservation of rights clause; and neither the Company nor any such subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or
to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.



		4.35	Each “employee benefit plan” (within the meaning of Section 3(3) of the Employee Retirement Security Act of 1974,
as amended (“ERISA”)) for which the Company or any member of its “Controlled Group” (defined
as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the Internal Revenue
Code of 1986, as amended (the “Code”)) would have any liability (each a “Plan”)
has been maintained in compliance with its terms and with the requirements of all applicable statutes, rules and regulations including
ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has
occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii) with
respect to each Plan subject to Title IV of ERISA (A) no “reportable event” (within the meaning of Section 4043(c)
of ERISA) has occurred or is reasonably expected to occur, (B) no Plan is or is reasonably expected to be “at risk”
status (within the meaning of Section 430 of the Code or Section 303 of ERISA) (C) there has been no filing pursuant to Section
412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any
Plan or the receipt by the Company or any member of its Controlled Group from the Pension Benefit Guaranty Corporation or the plan
administrator of any notice relating to the intention to terminate any Plan or Plans or to appoint a trustee to administer any
Plan, (D) no conditions contained in Section 303(k)(1)(A) of ERISA for imposition of a lien shall have been met with respect to
any Plan and (E) neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability
under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation in the ordinary
course and without default) in respect of a Plan (including a “multiemployer plan”, within the meaning of Section 4001(c)(3)
of ERISA) (“Multiemployer Plan”); (iv) no Multiemployer Plan is, or is expected to be, “insolvent”
(within the meaning of Section 4245 of ERISA), in “reorganization” (within the meaning of Section 4241 of ERISA), or
in “endangered” or “critical” status (within the meaning of Section 432 of the Code or Section 304 of ERISA);
and (v) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether
by action or by failure to act, which would cause the loss of such qualification.







    	 	A-11	 



     

    

 


		4.36	No subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the Company, from
making any other distribution on such subsidiary’s capital stock or other ownership interests, from repaying to the Company
any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s property or assets
to the Company or any other subsidiary of the Company, except as described in the Public Disclosure Documents.



		4.37	Immediately after the consummation of the issuance of the Notes, the Company will be Solvent. As used in this paragraph, the
term “Solvent” means, with respect to a particular date, that on such date (i) the present fair market
value (or present fair saleable value) of the assets of the Company are not less than the total amount required to pay the probable
liabilities of the Company on its total existing debts and liabilities (including contingent liabilities) as they become absolute
and matured, (ii) the Company is able to realize upon its assets and pay its debts and other liabilities, contingent obligations
and commitments as they mature and become due in the normal course of business, (iii) assuming the sale of the Notes as contemplated
herein, the Company is not incurring debts or liabilities beyond its ability to pay as such debts and liabilities mature, (iv)
the Company is not engaged in any business or transaction, and is not about to engage in any business or transaction, for which
its property would constitute unreasonably small capital after giving due consideration to the prevailing practice in the industry
in which the Company is engaged, and (v) the Company is not a defendant in any civil action that would result in a judgment that
the Company is or would become unable to satisfy. In computing the amount of such contingent liabilities at any time, it is intended
that such liabilities will be computed at the amount that, in the light of all the facts and circumstances existing at such time,
represents the amount that can reasonably be expected to become an actual or matured liability.







    	 	A-12	 



     

    

 


		4.38	Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other
than this Agreement) that could give rise to a valid claim against any of them for a brokerage commission, finder’s fee or
like payment in connection with the sale of the Notes.



		4.39	Neither the Company nor any of its subsidiaries is in violation of or has received notice of any violation with respect to
any federal or state law relating to discrimination in the hiring, promotion or pay of employees, nor any applicable federal or
state wage and hour laws, nor any state law precluding the denial of credit due to the neighborhood in which a property is situated,
the violation of any of which could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.







    	 	A-13	 



     

    

 


		4.40	Except as described in the Public Disclosure Documents, and except, in each case, where such event could not, individually
or in the aggregate, reasonably be expect to have a Material Adverse Effect, the Company and each of its subsidiaries: (i) has
not received any unresolved U.S. Food and Drug Administration (“FDA”) or similar governmental agency
or body (“Governmental Authority”) written notice of inspectional observations, Form 483, written notice
of adverse filing, warning letter, untitled letter or other similar correspondence or notice from the FDA, or any other court or
arbitrator or federal, state, local or foreign governmental or regulatory authority, alleging or asserting material noncompliance
with the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.), or received any written requests or requirements to
make material changes to the Company products by the FDA or any other Governmental Authority, (ii) is and has been in compliance
with applicable health care laws, including, the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.), the federal
Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the criminal
False Claims Law (42 U.S.C. § 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), the Physician Payment
Sunshine Act (42 U.S.C. § 1320a-7h), all criminal laws relating to health care fraud and abuse, including but not limited
to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability
Act of 1996 (42 U.S.C. § 1320d et seq.) (“HIPAA”), the exclusion laws (42 U.S.C. § 1320a-7),
Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), HIPAA, as amended by the Health
Information Technology for Economic and Clinical Health Act of 2009, and the regulations promulgated pursuant to such laws, and
comparable state laws, and all other foreign, federal, state and local laws relating to the regulation of the Company and its subsidiaries
(collectively, “Health Care Laws”), (iii) has not engaged in activities which are, as applicable, cause
for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state health
care program or federal health care program, (iv) possesses all Permits and supplements or amendments thereto required by any such
Health Care Laws and/or to carry on its businesses as currently conducted as described in the Public Disclosure Documents (“Authorizations”),
and such Authorizations are valid and in full force and effect and neither the Company nor any of its subsidiaries is in violation
of any term of any such Authorizations, (v) has not received written notice of any ongoing claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any Governmental Authority alleging that any product, operation or
activity is in material violation of any Health Care Laws or Authorizations and has no knowledge that any such Governmental Authority
has threatened any such claim, litigation, arbitration, action, suit, investigation or proceeding, (vi) has not received written
notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations
and has no knowledge that any such Governmental Authority has threatened such action, (vii) has filed, obtained, maintained or
submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments thereto
as required by any Health Care Laws or Authorizations and all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were complete, correct and not misleading on the date filed (or were corrected or supplemented
by a subsequent submission), (viii) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to
be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, “dear doctor”
letter, or other notice or action relating to the alleged lack of safety, efficacy or regulatory compliance of any product or any
alleged product defect or violation and, to the Company’s knowledge, there are no facts which are reasonably likely to cause,
and the Company has not received any written notice from the FDA or any other Governmental Authority regarding, a material recall,
market withdrawal or replacement of any Company product sold or intended to be sold by the Company, a material change in the marketing
classification or a material adverse change in the labeling of any such Company products, or a termination or suspension of the
manufacturing, marketing, or distribution of such Company products, (ix) is not a party to any corporate integrity agreement, deferred
prosecution agreement, monitoring agreement, consent decree, settlement order, or similar agreements, or has any reporting obligations
pursuant to any such agreement, plan or correction or other remedial measure entered into with any Governmental Authority, (x)
has not, nor has any officer, director, employee, agent or, to the knowledge of the Company, any distributor of the Company, made
an untrue statement of a material fact or a fraudulent statement to the FDA or any other Governmental Authority, failed to disclose
a material fact required to be disclosed to the FDA or any other Governmental Authority, or committed an act, made a statement,
or failed to make a statement, in each such case, related to the business of the Company that, at the time such disclosure was
made, would reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements
of Material Facts, Bribery, and Illegal Gratuities”, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for the FDA
or any other Governmental Authority to invoke any similar policy, (xi) has not, nor has any officer, director, employee, or, to
the knowledge of the Company, any agent or distributor of the Company, been debarred or convicted of any crime or engaged in any
conduct for which debarment is mandated by 21 U.S.C. § 335a(a) or any similar law or authorized by 21 U.S.C. § 335a(b)
or any similar law applicable in other jurisdictions in which Company products or Company product candidates are sold or intended
by the Company to be sold, and (xii) neither the Company, its subsidiaries nor their officers, directors, employees, agents or
contractors has been or is currently debarred, suspended or excluded from participation in the Medicare and Medicaid programs or
any other state or federal health care program.







    	 	A-14	 



     

    

 


		4.41	The preclinical tests and clinical trials conducted or sponsored by, or on behalf of the Company and its subsidiaries were
and, if still pending, are being conducted in all material respects in accordance with protocols filed with the appropriate regulatory
authorities for each such test or trial, as the case may be, and with standard medical and scientific research procedures and applicable
laws, regulations and Authorizations, including without limitation, those of the FDA; each description of the results of such tests
and trials contained in the Public Disclosure Documents is accurate and complete in all material respects and fairly presents the
data derived from such tests and trials, and the Company and its subsidiaries have no knowledge of any other studies or tests the
results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Public Disclosure
Documents; and neither the Company nor any of its subsidiaries has received any notices or other correspondence from the FDA, the
U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical
device regulatory agency requiring the termination, suspension or modification of any clinical trials..



		4.42	So long as any of the Notes or the Underlying Common Stock are outstanding, the Company will furnish at its expense, upon request,
to the holders of the Notes or the Underlying Common Stock and prospective purchasers of the Notes or the Underlying Common Stock
the information, if any, required by Rule 144A(d)(4) under the Securities Act.



		4.43	The Company and its affiliates will not take, directly or indirectly, any action designed to or that has constituted or that
reasonably could be expected to cause or result in the stabilization or manipulation of the price of any security of the Company
in connection with the sale of the Notes.



		4.44	The Company agrees not to sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any “security”
(as defined in the Securities Act) that would be integrated with the sale of the Notes in a manner that would require the registration
under the Securities Act of the sale of the Notes to the Investors. The Company will take any reasonable precautions designed to
insure that any offer or sale, direct or indirect of any Notes or any substantially similar security issued by the Company, within
six months subsequent to the date on which the distribution of the Notes has been completed, is made under restrictions and other
circumstances reasonably designed not to affect the status of the sale of the Notes contemplated by this Agreement, as transactions
exempt from the registration provisions of the Securities Act, including any sales pursuant to Rule 144A under, or Regulation D
of, the Securities Act.







    	 	A-15	 



     

    

 


		4.45	In connection with any offer or sale of the Notes, the Company will not engage, and will cause its affiliates and any person
acting on its behalf not to engage in any form of general solicitation or general advertising (within the meaning of Regulation
D of the Securities Act), or any “public offering” within the meaning of Section 4(a)(2) of the Securities Act in connection
with any sale of the Notes.



		4.46	The Company agrees to reserve and keep available at all times, free of preemptive rights, a sufficient number of Underlying
Common Stock to enable the Company to satisfy any obligations to issue Underlying Common Stock upon conversion of the Notes.



		4.47	On and after the date hereof to, and including, the Closing Date, the Company will not do or authorize any act that would result
in an adjustment of the conversion rate of the Notes.








 


		5.	Representations, Warranties and Covenants of the Company.



The Company hereby represents and warrants
to, and covenants with, each Investor that:



		5.1	(1)	Each Investor is (a)
either a QIB as defined in Rule 144A under the Securities Act, or an institutional accredited investor as defined in Rule 501(a)(1),
(a)(2), (a)(3), or (a)(7) under the Securities Act, as presently in effect, (b) aware that the sale to it is being made in reliance
on a private placement exemption from registration under the Securities Act, and (c) acquiring the Securities for its own account
or for the account of a QIB or an institutional accredited investor.




		(2)	Each Investor understands and agrees on behalf of itself and on behalf of any investor account for which it is purchasing the
Securities and Common Stock issuable upon conversion of the Securities, that the Securities and Common Stock issuable upon conversion
of the Securities are being offered in a transaction not involving any public offering within the meaning of the Securities Act,
that the Securities and Common Stock issuable upon conversion of the Securities have not been, and will not be, registered under
the Securities Act and that (a) if it decides to offer, resell, pledge or otherwise transfer any of the Securities or Common Stock
issued upon conversion of the Securities, such Securities and Common Stock may be offered, resold, pledged or otherwise transferred
only (i) to a person whom the seller reasonably believes is a QIB in a transaction meeting the requirements of Rule 144A, (ii)
pursuant to any other exemption from the registration requirements of the Securities Act, including Rule 144 under the Securities
Act (if available), (iii) pursuant to an effective registration statement under the Securities Act, or (iv) to the Company, or
one of its subsidiaries, in each of cases (i) through (iv) in accordance with any applicable securities laws of any state of the
United States.



		(3)	Each Investor understands that the Securities and Common Stock issued upon conversion of the Securities will, unless sold pursuant
to a registration statement that has been declared effective under the Securities Act or in compliance with Rule 144, and will
bear a legend that reflects the restricted nature of the securities.








    	 	A-16	 



     

    

 


		(4)	Each Investor:



		(a)	is able to fend for itself in the transactions contemplated hereby;



		(b)	has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of
its prospective investment in the Securities; and



		(c)	has the ability to bear the economic risks of its prospective investment and can afford the complete loss of such investment.



		(5)	Each Investor acknowledges that (a) it has conducted its own investigation of the Company and the terms of the Securities,
(b) it has had access to, and has had an adequate opportunity to review, (i) all information the Company has filed with and furnished
to the Commission, (ii) all information set forth in such filings and (iv) such financial and other information as it deems necessary
to make its decision to purchase the Securities, and (c) it has been offered the opportunity to ask questions of the Company, and
received such answers thereto, as it deemed necessary in connection with the decision to purchase the Securities.



		(6)	Each Investor understands that the Company, and others will rely upon the truth and accuracy of the foregoing representations,
acknowledgements and agreements and agrees that if any of the representations and acknowledgements deemed to have been made by
it by its purchase of the Securities are no longer accurate, such Investor shall promptly notify the Company. If such Investor
is acquiring the Securities as a fiduciary or agent for one or more investor accounts, it represents that it has sole investment
discretion with respect to each such account and it has full power to make the foregoing representations, acknowledgements and
agreements on behalf of such account.




		5.2	Each Investor acknowledges that no action has been or will be taken in any jurisdiction outside
the United States by the Company that would permit an offering of the Securities, or possession or distribution of offering materials
in connection with the issue of the Securities (including any filing of a registration statement),
in any jurisdiction outside the United States where action for that purpose is required. Each
Investor outside the United States will comply with all applicable laws and regulations in each
foreign jurisdiction in which it purchases, offers, sells or delivers Securities or has in its possession or distributes
any offering material, in all cases at its own expense.








    	 	A-17	 



     

    

 


		5.3	Each Investor has full right, power, authority and capacity to enter into this Agreement and
to consummate the transactions contemplated hereby and has taken all necessary action to authorize
the execution, delivery and performance of this Agreement, and this Agreement constitutes
a valid, binding and enforceable obligation of such Investor, except as the enforceability
of the Agreement may be subject to or limited by bankruptcy, insolvency, reorganization, arrangement, moratorium or other
similar laws relating to or affecting the rights of creditors generally.



		5.4	The entry into and performance of this Agreement by each Investor and the consummation by such Investor of the transactions
contemplated hereby and thereby will not (i) result in a violation of the organizational documents of Investor, (ii) conflict with,
or constitute a default under, or give to others any rights of termination, amendment, acceleration or cancellation of any agreement,
indenture or instrument to which such Investor is party, or (iii) result in the violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws) applicable to such Investor, except in the case of clauses (ii)
and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably
be expected to have a material adverse effect on the ability of such Investor to perform its obligations hereunder.



		5.5	Each Investor understands that nothing in this Agreement, information the Company has filed with and furnished to the Commission
or any other materials presented to such Investor in connection with the purchase and sale of the Securities constitutes legal,
tax or investment advice. Each Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has
deemed necessary or appropriate in connection with its purchase of the Securities and has made its own assessment and has satisfied
itself concerning the relevant tax and other economic considerations relevant to its investment in the Securities.



		6.	Survival of Representations, Warranties and Agreements. Notwithstanding any investigation made by any party to
this Agreement, all covenants, agreements, representations and warranties made by the Company and the Investors herein shall survive
the execution of this Agreement, the delivery to the Investors of the Securities being purchased and the payment therefor.



		7.	Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be delivered
(A) if within the domestic United States, by first-class registered or certified mail, or nationally recognized overnight express
courier, postage prepaid, or by facsimile, or (B) otherwise by International Federal Express or facsimile, and shall be deemed
given (i) if delivered by first-class registered or certified mail, three business days after so mailed, (ii) if delivered by a
nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International Federal Express,
two business days after so mailed and (iv) if delivered by facsimile, upon electronic confirmation of receipt and shall be delivered
as addressed as follows:



(a) if to the Company, to:


Xtant Medical Holdings, Inc.


600 Cruiser Lane


Belgrade, Montana 59714


Attention: General Counsel


(b) if to the Investors, at each Investor’s
address on the signature page hereto, or at such other address or addresses as may have been furnished to the Company in writing.


 






    	 	A-18	 



     

    

 


		8.	Changes. Except as contemplated herein, this Agreement may not be modified or amended except pursuant to an instrument
in writing signed by the Company and each Investor.



		9.	Headings. The headings of the various sections of this Agreement have been inserted for convenience or reference
only and shall not be deemed to be part of this Agreement.



		10.	Severability. In case any provision contained in this Agreement should be invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected
or impaired thereby.



		11.	Applicable Law; Venue. This Agreement will be governed by and construed in accordance with the laws of the State
of New York applicable to contracts made and to be performed within the State of New York. Each of the Company and each Investor
agrees that any suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby
may be instituted only in any State or U.S. federal court in The City of New York and County of New York and waives any
objection that such party may now or hereafter have to the laying of venue of any such suit, action or proceeding, and irrevocably
submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.



		12.	Waiver of Jury Trial. Each of the Company and each Investor hereby irrevocably waives, to the fullest extent
permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement
or the transactions contemplated hereby.



		13.	Counterparts. This Agreement may be signed in one or more counterparts, each of which shall constitute an original
and all of which together shall constitute one and the same agreement.



		14.	Payment of Expenses. The Company agrees to pay on demand all expenses of the Investors (including, without limitation,
the fees and out-of-pocket expenses of Covington & Burling LLP, counsel to the Investors) incurred in connection with the Investors’
review, consideration and evaluation of this Agreement, the Securities and the Registration Rights Agreement, including the rights
and remedies available to it in connection therewith, and the negotiation, preparation, execution and delivery of this Agreement,
the Securities and the Registration Rights Agreement.



 






    	 	A-19